Sawtooth Solutions LLC Acquires Shares of 1,292 Shire PLC (SHPG)

Sawtooth Solutions LLC acquired a new stake in Shire PLC (NASDAQ:SHPG) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,292 shares of the biopharmaceutical company’s stock, valued at approximately $200,000.

Other hedge funds have also recently added to or reduced their stakes in the company. SeaCrest Wealth Management LLC purchased a new position in Shire in the fourth quarter valued at about $107,000. Avestar Capital LLC purchased a new position in Shire in the fourth quarter valued at about $116,000. Amica Retiree Medical Trust purchased a new position in Shire in the fourth quarter valued at about $120,000. BB&T Investment Services Inc. grew its stake in Shire by 1,672.3% in the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 786 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC purchased a new position in Shire in the third quarter valued at about $159,000. Hedge funds and other institutional investors own 19.59% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several equities analysts have issued reports on the company. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research note on Friday. BidaskClub lowered Shire from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Cantor Fitzgerald set a $222.00 target price on Shire and gave the company a “buy” rating in a research note on Wednesday, March 7th. ValuEngine lowered Shire from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Royal Bank of Canada set a $192.00 target price on Shire and gave the company a “buy” rating in a research note on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. Shire currently has an average rating of “Buy” and a consensus price target of $204.00.

Shares of Shire PLC (NASDAQ SHPG) opened at $126.50 on Monday. Shire PLC has a 52 week low of $123.73 and a 52 week high of $192.15. The firm has a market capitalization of $38,374.66, a PE ratio of 8.35, a PEG ratio of 0.73 and a beta of 1.44. The company has a current ratio of 0.97, a quick ratio of 0.55 and a debt-to-equity ratio of 0.46.

Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.86 by $0.12. Shire had a return on equity of 14.19% and a net margin of 28.17%. The business had revenue of $4.14 billion for the quarter. During the same quarter in the previous year, the firm posted $3.37 EPS. Shire’s revenue was up 8.9% on a year-over-year basis. research analysts forecast that Shire PLC will post 15.23 EPS for the current fiscal year.

The firm also recently declared a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be paid a dividend of $0.8937 per share. This is a positive change from Shire’s previous semiannual dividend of $0.15. The ex-dividend date is Thursday, March 8th. This represents a dividend yield of 1.33%. Shire’s payout ratio is presently 7.47%.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3302311/sawtooth-solutions-llc-acquires-shares-of-1292-shire-plc-shpg.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Dicerna Pharmaceuticals’  Outperform Rating Reiterated at Evercore ISI
Dicerna Pharmaceuticals’ Outperform Rating Reiterated at Evercore ISI
Gregory L. Hart Sells 4,000 Shares of United Continental Holdings  Stock
Gregory L. Hart Sells 4,000 Shares of United Continental Holdings Stock
TT Electronics  To Go Ex-Dividend on April 26th
TT Electronics To Go Ex-Dividend on April 26th
Woodward  Stock Rating Upgraded by Zacks Investment Research
Woodward Stock Rating Upgraded by Zacks Investment Research
Albireo Pharma  Earns Outperform Rating from Wedbush
Albireo Pharma Earns Outperform Rating from Wedbush
Banner  Downgraded by Zacks Investment Research to “Sell”
Banner Downgraded by Zacks Investment Research to “Sell”


© 2006-2018 Ticker Report. Google+.